Bevacizumab Plus Temozolomide Produces Low Response in Newly-Diagnosed Glioblastoma
the Cancer Therapy Advisor take:
Combination bevacizumab (BV) with radiotherapy and temozolomide (TMZ) is safe and feasible in patients with newly-diagnosed glioblastoma multiforme (GBM), but low response rates do not favor a neoadjuvant approach, according to a recent study published in The Oncologist.
Myra van Linde, MD, and fellow researchers from the VU Medical Center in The Netherlands observed 19 patients, with six after biopsy and 13 after resection.
“We hypothesized that a neoadjuvant treatment strategy for patients with newly-diagnosed GBM using chemoradiotherapy plus BV would improve respectability and thus survival,” the authors noted.
In their phase II trial, patients received radiotherapy with combination BV and TMZ on days 1, 14, and 28, followed by six monthly cycles of TMZ on days 1 to 5.
They found that the overall response rate was 26 percent, with three who had a complete response after resection and two who had complete response after resection followed by chemoradiation with BV. Median overall survival was 16 months which was similar to a matched control group that received standard chemoradiotherapy at the VU Medical Center.
Combination bevacizumab with radiotherapy and temozolomide is safe in glioblastoma, but low response rates do not favor a neoadjuvant approach.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Plastics and Cancer
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Emetogenic Potential of Antineoplastic Agents
- 20-Year Data Link High-Dose Chemotherapy and Hematopoietic Stem Cell Transplant to Survival Benefit in High-Risk Early Breast Cancer
- Cabozantinib Shows Promising Activity in Osteosarcoma and Ewing Sarcoma
- Reducing Trastuzumab Duration Lowers Costs by Nearly £10,000 in HER2-positive Breast Cancer
- Resistance Mechanisms Identified for NSCLC Progression With First-Line Osimertinib
- Atezolizumab and Nab-Paclitaxel Prolonged PFS in Metastatic Triple-Negative Breast Cancer